How many drugs treat Hemorrhoids?

Drug Landscape tracks 10 marketed treatments for Hemorrhoids (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/hemorrhoids.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Hemorrhoids — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hemorrhoids (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Hemorrhoids, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Galzin	ZINC ACETATE	Eton	zinc acetate		1980-01-01
Sudafed PE	phenylephrine	Generic (multiple manufacturers)	Alpha-1 adrenergic agonist (decongestant/vasopressor)	Alpha-1A adrenergic receptor, Alpha-1B adrenergic receptor, Alpha-1D adrenergic receptor	1976-01-01
Cortef	hydrocortisone	Generic (originally Merck/Upjohn)	Corticosteroid [EPC]	Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible	1952-01-01
Phenergan Vc W/ Codeine	PHENYLEPHRINE BITARTRATE	ANI Pharmaceuticals	Nonsteroidal Anti-inflammatory Drug [EPC]	Alpha-1B adrenergic receptor	1952-01-01
Cortifoam	HYDROCORTISONE ACETATE	Pfizer	Corticosteroid	Corticosteroid-binding globulin	1951-01-01
Lignospan Forte	Lidocaine Hydrochloride	Fresenius Kabi	local anesthetic, amide type	neuronal membrane ionic channels	1948-01-01
xylocain	xylocain	Saint-Joseph University		5-hydroxytryptamine receptor 3A, Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4, Sodium channel protein type 10 subunit alpha
Lignocaine	Lignocaine	University of Malaya		5-hydroxytryptamine receptor 3A, Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4, Sodium channel protein type 10 subunit alpha
Cortisol	Cortisol	University of Zurich		Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible
Lidocain	Lidocain	Bayer		5-hydroxytryptamine receptor 3A, Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4, Sodium channel protein type 10 subunit alpha

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 4 drugs in Hemorrhoids
ANI Pharmaceuticals · 1 drug in Hemorrhoids
Bayer · 1 drug in Hemorrhoids
Eton · 1 drug in Hemorrhoids
Fresenius Kabi · 1 drug in Hemorrhoids
Generic (multiple manufacturers) · 1 drug in Hemorrhoids
Generic (originally Merck/Upjohn) · 1 drug in Hemorrhoids
Pfizer · 1 drug in Hemorrhoids
Saint-Joseph University · 1 drug in Hemorrhoids
University of Malaya · 1 drug in Hemorrhoids
University of Zurich · 1 drug in Hemorrhoids
WU XI ZHONG ZHI WEI NA TECHNOLOGY CO., Ltd. · 1 drug in Hemorrhoids

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Hemorrhoids:

Cite this brief

Drug Landscape (2026). Hemorrhoids — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/hemorrhoids. Accessed 2026-06-10.

Hemorrhoids full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing